Related references
Note: Only part of the references are listed.Evaluation of antigenicity and cell mediated immunity of Hepatitis E virus patients: Using non radioactive MTT assay
M. Majumdar et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2013)
HMGB1 cytoplasmic translocation in patients with acute liver failure
Rong-Rong Zhou et al.
BMC GASTROENTEROLOGY (2011)
Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients
Li-feng Huang et al.
CYTOKINE (2011)
Adaptive immune responses during acute uncomplicated and fulminant hepatitis E
Ratika Srivastava et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Glycyrrhizin Prevents Liver Injury by Inhibition of High-Mobility Group Box 1 Production by Kupffer Cells after Ischemia-Reperfusion in Rats
Masahito Ogiku et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The role of HMGB1 in the pathogenesis of rheumatic disease
Ulf Andersson et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
Viral Load, Antibody Titers and Recombinant Open Reading Frame 2 Protein-Induced Th1/Th2 Cytokines and Cellular Immune Responses in Self-Limiting and Fulminant Hepatitis E
S. Saravanabalaji et al.
INTERVIROLOGY (2009)
Dengue virus infection promotes translocation of high mobility group box 1 protein from the nucleus to the cytosol in dendritic cells, upregulates cytokine production and modulates virus replication
Edwin Kamau et al.
JOURNAL OF GENERAL VIROLOGY (2009)
High-Mobility Group Box 1 Protein in CSF of Patients with Subarachnoid Hemorrhage
Takashi Nakahara et al.
NEUROCRITICAL CARE (2009)
Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma
B. -Q. Cheng et al.
DIGESTIVE AND LIVER DISEASE (2008)
Hepatitis E vaccine
Rakesh Aggarwal et al.
HEPATOLOGY INTERNATIONAL (2008)
Beneficial drugs for liver diseases
Pablo Muriel et al.
JOURNAL OF APPLIED TOXICOLOGY (2008)
Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities
Luca Mollica et al.
CHEMISTRY & BIOLOGY (2007)
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice
Giovanni Sitia et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Role of HMGB1 in cardiovascular diseases
W Li et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Potential role of high mobility group box 1 in viral infectious diseases
HC Wang et al.
VIRAL IMMUNOLOGY (2006)
Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells
C Fiuza et al.
BLOOD (2003)
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway
S Gardella et al.
EMBO REPORTS (2002)
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
L Ulloa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
P Scaffidi et al.
NATURE (2002)
HMGB1 as a late mediator of lethal systemic inflammation
HH Wang et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
The systemic inflammatory response syndrome in acute liver failure
N Rolando et al.
HEPATOLOGY (2000)
Anti-inflammatory therapies in sepsis and septic shock
BD Freeman et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Share Paper
